Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022 report gives
comprehensive insight on clinical & non-clinical issues involved with growth of global
biosimilar insulin market. This report analyzes various aspects like rationale design of insulin
molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects
of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight &
future trends for the development of biosimilar insulin market.

The development of biosimilar was a consequence of the financial success of the biologic
therapies & their inevitable patent cliff a marked drop in sales as they near the expiration of
their original patents. Biosimilar development represents a large profit potential for
pharmaceutical manufacturers. Consumers & policy makers view appropriate market
introduction of biosimilars as high priority because of the prospect of reduced medical costs.

The consequence of recent technological innovations, new regulations in the

biopharmaceutical industry, & cost concerns, the idea of biosimilars has gathered attention
towards them & their potential future market. In fact, efforts are already underway to
develop a new class of follow-on biologics named biobetters or biosuperiors, which go beyond
mimicking the original biologic to provide improvements through changes in chemistry,
alteration in the formulation, & innovative delivery.

The potential of insulin biosimilars like Basaglar is huge in the upcoming future, the dem&
will significantly grow in developed market as the countries including US, Europe & Japan
have shown a great enthusiasm towards biosimilar products especially Europe. The developed
market somehow, with the exception of the United States, has represented the greatest
biosimilars presence today. Most biosimilars manufacturers have been & remain focused on
the developed markets whether it is for their historic & current opportunities (EU) or for their
future market potential (United States, Japan).

Devoted regulatory pathways set the foundation for stringent, abbreviated approval processes
which, in turn, have nourished investor interest. Biosimilars adoption in developed markets
has been primarily payer-driven, especially in European markets, given payers urgent, unmet
need to contain public health care expenditures. Thus similar hopes are confined with the
biosimilar insulins.

For Report Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 1

 Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022

In contrary to the developed world, developing countries tends to believe more in biosimilar
versions of essential drugs. Like India & China are developing biosimilar versions of insulin
from past several years but did not gained popularity due to the lack of biosimilar regulatory
framework. However, in contrasting emerging markets with developed markets, the limited
patient access to affordable biologics & the openness of physicians to low cost therapies
offers potentially significant opportunities.

Certainly the future for biosimilar insulin is brightened by the increasing prevalence of
diabetes, high cost of br&ed insulins & the patent cliff scenarios. The expected entry of
biosimilars onto the insulin market could significantly change the insulin l&scape in the
coming years. These products could have a notable impact on diabetes treatment costs,
accessibility of insulin, insulin market competition, & the number of insulin choices available
to patients. However, biosimilar companies will face major challenges on regulatory,
commercial, & competitive fronts as they seek to enter this market.

For Report Sample Contact: neeraj@kuickresearch.com

For Report Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 2

 Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022

Table of Contents
Prologue to Insulin Biosimilars

1.1 Outline Towards Insulin

1.2 Trail of Insulin Evolution & Development

Rationale Design of Insulin Molecule

2.1 Structure of Insulin Polypeptide

2.2 Biosynthesis of Insulin

2.3 Secretion of Insulin

Mechanism of Insulin in Diabetics

3.1 Glucose Metabolism of Insulin

3.2 Impact of Insulin Dysregulation in Diabetes 1

3.3 Impact of Insulin Resistance in Diabetes 2

Engineering of Synthetic Insulin

4.1 Production of Human Insulin

4.2 Categorization of Insulin & Its Analogues

4.2.1 Rapid Acting Insulins

4.2.2 Short Acting Insulins

4.2.3 Intermediate Insulin

4.2.4 Long Lasting Insulins

Insulinotherapeutics in Diabetes

5.1 Conventional Insulinotherapy

5.2 Flexible or Intensive Insulinotherapy

Global Economic Aspects of Insulin

6.1 Skyrocketing Cost of Insulin Therapies

6.2 Emergence of Biosimilar

For Report Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 3

 Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022

Global Economic Cost of Diabetes

7.1 Monetary Burden of Diabetes

7.2 US

7.3 Europe

7.4 Japan

7.5 China

7.6 India

Global Aspects of Biosimilar Insulins

8.1 US

8.2 Europe

8.3 Japan

8.4 Asia (Excluding Japan)

Global Biosimilar Insulin Market Overview

9.1 Preface to Biosimilar Insulin Market

9.2 Biosimilar Competition Assessment

Global Biosimilar Insulin Clinical Pipeline Insight

Marketed Biosimilar Insulin Clinical Insight by Company, Indication & Phase

11.1 Insulin Biosimilar (Wosulin-R)

11.2 Insulin Glargine Biosimilar (Glaritus, Glaritus Cart, Glaritus DispoPen)

11.3 Insulin Glargine Biosimilar (Abasaglar, Abasria & Basalgar)

11.4 Insulin Suspension Isophane/Insulin Biosimilar (Jusline 30/70)

11.5 Insulin Glargine Biosimilar (Basalog & GALACTUS)

11.6 Insulin Suspension Isophane Biosimilar (Jusline N)

11.7 Insulin Suspension Isophane/Insulin Biosimilar (Insulin H Mix)

11.8 Insulin Suspension Isophane Biosimilar (Insulin Hbio NPH)

11.9 Insulin Biosimilar (Insulin Hbio R)

For Report Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 4

 Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022

11.10 Insulin Glargine Biosimilar (Basalin)

11.11 Insulin/Insulin Suspension Isophane Biosimilar (Wosulin 30/70, 50/50)

11.12 Insulin Suspension Isophane Biosimilar (Wosulin-N)

11.13 Insulin Biosimilar (Jusline R)

11.14 Insulin Glargine Biosimilar (Basugine)

11.15 Insulin Biosimilar (Insugen)

Biosimilar Insulin Future Targeted Market

12.1 Global High Prevalence of Diabetics

12.2 Global Prevalence of Obesity

Global Biosimilar Insulin Market Dynamics

13.1 Accelerating Parameters

13.2 Major Challenges of Biosimilar Insulin Market

Future Implications of Biosimilar Insulin

Competitive L&scape

15.1 Biocon

15.2 Biogenomics

15.3 Eli Lilly

15.4 Gan&Lee Pharmaceuticals

15.5 Geropharm

15.6 Julphar Gulf Pharmaceutical Industries

15.7 Paras Biopharmaceuticals

15.8 Samsung Bioepis

15.9 Sedico

15.10 Wockhardt

For Report Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 5

 Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022

List of Figures
Figure 1-1: Major Historical Events in Discovering Insulin
Figure 2-1: Primary Structure of Insulin with Polypeptidic Chains
Figure 2-2: Illustration of Biosynthesis from Preproinsulin to Proinsulin
Figure 2-3: Mechanism of Insulin Release from the Pancreas
Figure 3-1: Mechanism of glucose Uptake by Insulin Molecule
Figure 3-2: Deficiency of Insulin Leading towards the Type I Diabetes
Figure 3-3: Insulin resistance Shown by the Type 2 Diabetes
Figure 4-1: Process of Generating Recombinant Insulin in Bacterial Cell
Figure 4-2: Different Types of Insulin & Their Br& Names with Time of Action
Figure 5-1: Relationships among Components of Insulin, Injection Times & Blood Glucose
Testing
Figure 5-2: Insulin Release during Conventional Insulinotherapy
Figure 5-3: Insulin release at Intensified or Flexible Insulinotherapy
Figure 6-1: Representation of Rising Cost of Insulin per Unit
Figure 7-1: Illustration of the Total Cost Distribution of Diabetes
Figure 7-2: Global Estimated Total Expenditure of Diabetes (US$ Billion), 2015 & 2040
Figure 7-3: Top 10 Countries by Highest Spending Per Patient with Diabetes (US$)
Figure 7-4: Top 10 Countries by Lowest Spending Per Patient with Diabetes (US$)
Figure 7-5: US - Estimated Total Cost of Diabetes & Obesity (US$ Billion)
Figure 7-6: Representation of Cost of Insulin among Different Countries, 2016
Figure 7-7: Projected Cost of Diabetes in Europe
Figure 7-8: Estimated Prevalence of Diabetes in Japan (In Million)
Figure 7-9: Projected Number of Diabetic Cases in China (Million)
Figure 7-10: India - Increasing Prevalence of Diabetes & Future Projections (Million)
Figure 8-1: Demonstration Comparative Price of Lantus Insulin in US & Other Countries
Figure 8-2: Highest Growth in Number of Biosimilars C&idates in South East Asian Region
Figure 9-1: Cost savings with Biosimilars & Generics as Compared to the Br&ed Versions
Figure 9-2: Global Insulin Market Assessment (US$ Billion), 2016-2022
Figure 9-3: Global Market Shares of Three Leading Companies in the Insulin Market
Figure 9-4: Illustrations of Lantus (Insulin Glargine) Revenues by Sanofis (Billion Euros)
Figure 9-5: Market Revenues of Novo Nordisk in Modern Insulin Market (DKK Billion)
Figure 10-1: Number of Biosimilar Insulin in Clinical Pipeline, 2017-2022
Figure 10-2: Biosimilar Insulin in Clinical Pipeline (%), 2017-2022
Figure 12-1: Top 5 Countries with High Diabetes Prevalence in Adults by 2030(in Millions)
Figure 12-2: Top 10 Countries by Highest Prevalence of Diabetes (%)
Figure 12-3: Global Increasing Prevalence of Diabetes Prevalence (In Millions)
Figure 12-4: Estimated Prevalence of Obesity among Various Countries (2025)
Figure 12-5: Increasing Relative Risk of Diabetes with Increasing BMI
Figure 13-1: Trends of High Cost of Insulin from 2010 till 2015 in US
Figure 13-2: The Major Favorable Parameters for Growth of Biosimilar Insulin Market
Figure 13-3: Major Barriers Encountered by the Insulin Biosimilar Market

For Report Sample Contact: neeraj@kuickresearch.com

For Report Sample Contact: neeraj@kuickresearch.com ; +91-11-47067990 Page 6